|Dr. Steven J. Mento||Co-Founder, Pres, CEO & Director||768.61k||N/A||1952|
|Dr. Keith W. Marshall MBA, Ph.D.||Exec. VP, COO & CFO||593.53k||N/A||1968|
|Dr. Alfred P. Spada||Co-Founder, Exec. VP of R&D and Chief Scientific Officer||N/A||N/A||1958|
|Mr. Alan R. Engbring||Exec. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
Conatus Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.